Puma Biotechnology, Inc.Find Ratings Reports
PUMA BIOTECHNOLOGY INC's gross profit margin for the second quarter of its fiscal year 2020 is essentially unchanged when compared to the same period a year ago. The company grew its sales and net income significantly quarter versus same quarter a year prior, and was able to outpace the average competitor in the subsector when comparing revenue growth, but not when comparing net income growth. PUMA BIOTECHNOLOGY INC has average liquidity. Currently, the Quick Ratio is 1.48 which shows that technically this company has the ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year, indicating deteriorating cash flow.
During the same period, stockholders' equity ("net worth") has increased by 7.49% from the same quarter last year. Together, the key liquidity measurements indicate that it is relatively unlikely that the company will face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q2 FY20||Q2 FY19|
|Net Sales ($mil)||70.58||53.92|
|Net Income ($mil)||3.4||-37.42|
|Balance Sheet||Q2 FY20||Q2 FY19|
|Cash & Equiv. ($mil)||116.12||117.67|
|Total Assets ($mil)||263.81||239.86|
|Total Debt ($mil)||120.58||119.77|
|Profitability||Q2 FY20||Q2 FY19|
|Gross Profit Margin||88.93||86.62|
|Return on Assets||-15.77||-38.52|
|Return on Equity||-177.84||-424.44|
|Debt||Q2 FY20||Q2 FY19|
|Share Data||Q2 FY20||Q2 FY19|
|Shares outstanding (mil)||39.63||38.74|
|Div / share||0.0||0.0|
|Book value / share||0.59||0.56|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||714859.0||1050912.0|
SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. For additional comparison, its price-to-book ratio of 16.05 indicates a significant premium versus the S&P 500 average of 3.73 and a significant premium versus the subsector average of 9.30. The price-to-sales ratio is well below both the S&P 500 average and the subsector average, indicating a discount. After reviewing these and other key valuation criteria, PUMA BIOTECHNOLOGY INC proves to trade at a premium to investment alternatives.
|PBYI NM||Peers 27.23||PBYI NM||Peers 21.73|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
PBYI's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
PBYI's P/CF is negative making the measure meaningless.
|PBYI NM||Peers 15.69||PBYI NA||Peers 0.83|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
PBYI's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|PBYI 16.05||Peers 9.30||PBYI 55.00||Peers 6.35|
Premium. A higher price-to-book ratio makes a stock less attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
PBYI is trading at a significant premium to its peers.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
PBYI is expected to have an earnings growth rate that significantly exceeds its peers.
|PBYI 1.56||Peers 436.31||PBYI -15.92||Peers 752.59|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
PBYI is trading at a significant discount to its subsector on this measurement.
Lower. A sales growth rate that trails the subsector implies that a company is losing market share.
PBYI significantly trails its peers on the basis of sales growth.